Skip to Content
MilliporeSigma
  • Sympathetic predominance is associated with impaired endothelial progenitor cells and tunneling nanotubes in controlled-hypertensive patients.

Sympathetic predominance is associated with impaired endothelial progenitor cells and tunneling nanotubes in controlled-hypertensive patients.

American journal of physiology. Heart and circulatory physiology (2014-05-27)
Elena M V de Cavanagh, Sergio A González, Felipe Inserra, Pedro Forcada, Carlos Castellaro, Jorge Chiabaut-Svane, Sebastián Obregón, María Jesús Casarini, Pablo Kempny, Carol Kotliar
ABSTRACT

Early endothelial progenitor cells (early EPC) and late EPC are involved in endothelial repair and can rescue damaged endothelial cells by transferring organelles through tunneling nanotubes (TNT). In rodents, EPC mobilization from the bone marrow depends on sympathetic nervous system activity. Indirect evidence suggests a relation between autonomic derangements and human EPC mobilization. We aimed at testing whether hypertension-related autonomic imbalances are associated with EPC impairment. Thirty controlled-essential hypertensive patients [systolic blood pressure/diastolic blood pressure = 130(120-137)/85(61-88) mmHg; 81.8% male] and 20 healthy normotensive subjects [114(107-119)/75(64-79) mmHg; 80% male] were studied. Mononuclear cells were cultured on fibronectin- and collagen-coated dishes for early EPC and late EPC, respectively. Low (LF)- and high (HF)-frequency components of short-term heart rate variability were analyzed during a 5-min rest, an expiration/inspiration maneuver, and a Stroop color-word test. Modulations of cardiac sympathetic and parasympathetic activities were evaluated by LF/HF (%) and HF power (ms(2)), respectively. In controlled-hypertensive patients, the numbers of early EPC, early EPC that emitted TNT, late EPC, and late EPC that emitted TNT were 41, 77, 50, and 88% lower than in normotensive subjects (P < 0.008), respectively. In controlled-hypertensive patients, late EPC number was positively associated with cardiac parasympathetic reserve during the expiration/inspiration maneuver (rho = 0.45, P = 0.031) and early EPC with brachial flow-mediated dilation (rho = 0.655; P = 0.049); also, late TNT number was inversely related to cardiac sympathetic response during the stress test (rho = -0.426, P = 0.045). EPC exposure to epinephrine or norepinephrine showed negative dose-response relationships on cell adhesion to fibronectin and collagen; both catecholamines stimulated early EPC growth, but epinephrine inhibited late EPC growth. In controlled-hypertensive patients, sympathetic overactivity/parasympathetic underactivity were negatively associated with EPC, suggesting that reducing sympathetic/increasing parasympathetic activation might favor endothelial repair.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Monoclonal Anti-CD14 antibody produced in mouse, clone UCHM-1, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
DL-Norepinephrine hydrochloride, crystalline, ≥97% (TLC)
Sigma-Aldrich
(±)-Norepinephrine (+)-bitartrate salt
Sigma-Aldrich
(−)-Norepinephrine, ≥98%, crystalline
Adrenaline with impurity F, European Pharmacopoeia (EP) Reference Standard
Adrenaline, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
sCD14 human, recombinant, expressed in HEK 293 cells, ≥95% (SDS-PAGE), ≥95% (HPLC), suitable for cell culture
Sigma-Aldrich
MISSION® esiRNA, targeting human CD14
Sigma-Aldrich
(−)-Epinephrine
Sigma-Aldrich
Monoclonal Anti-Vascular Endothelial Growth Factor Receptor-2 (KDR) antibody produced in mouse, clone 260.4, KDR-2, ascites fluid
Sigma-Aldrich
CD14 human, recombinant, expressed in E. coli, 0.5 mg protein/mL